ResearcherZhengzhou UniversityNo recent work listed
Yunjian Wang
Matched on ORCID iD 0000-0001-5228-4728; OpenAlex author ID A5043789884. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers
Papers 4
- Nanoparticles loaded with circ_0086375 for suppressing the tumorigenesis of pancreatic cancer by targeting the miR-646/SLC4A4 axis. Co-author DOI 10.1007/s10585-022-10197-0↗
- Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc. Co-author DOI 10.3892/ijo.2022.5456↗
- LINC01006 promotes cell proliferation and metastasis in pancreatic cancer via miR-2682-5p/HOXB8 axis. First author DOI 10.1186/s12935-019-1036-2↗
- [Expressions of stem cell factor and hypoxia inducible factor 1 alpha in pancreatic cancer cells and related mechanism]. First author PMID 28712399↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Luyang Zhang · 3 shared papers, 2019–2023 · strength 0.52
- Paper Nanoparticles loaded with circ_0086375 for suppressing the tumorigenesis of pancreatic cancer by targeting the miR-646/… DOI 10.1007/s10585-022-10197-0↗
- Paper Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc. DOI 10.3892/ijo.2022.5456↗
- Paper LINC01006 promotes cell proliferation and metastasis in pancreatic cancer via miR-2682-5p/HOXB8 axis. DOI 10.1186/s12935-019-1036-2↗
- Enze Wang · 2 shared papers, 2023 · strength 0.42
- Bo Meng · 2 shared papers, 2019–2023 · strength 0.29
- Qiong Li · 1 shared paper, 2023 · strength 0.18
- Min Zhang · 1 shared paper, 2023 · strength 0.18
- Min Zhang · 1 shared paper, 2019 · strength 0.10
- Ling Zhang · 1 shared paper, 2019 · strength 0.10
- Min Zhang · 1 shared paper, 2017 · strength 0.08
- Li Wang · 1 shared paper, 2017 · strength 0.08
- Nanmu Yang · 1 shared paper, 2017 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.